Lilly, Boehringer to slash at least $1B each from planned investments in Germany

Eli Lilly and Boehringer Ingelheim are cutting back on planned investments in Germany in response to a new government healthcare initiative, representatives for the companies told Fierce. In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research…

Source: FierceBiotech